您的位置:PharmaNews 研发动态 正文
内容搜索
热门内容
推荐内容
最新内容
反馈意见和建议

WaferGen Announces Purchase of SmartChip Products by Contract Services Company Directed by Founder and Organizer of Japanese Human Genome Project(3)
本文章共4640字,分3页,当前第3页,快速翻页:


 

Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that: (i) the company may be unsuccessful in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (ii) the company will need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable terms or at all; (iii) the company's proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2009 and the Form 10Q for the quarter ended March 31, 2010. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
 


  Contacts:
  WaferGen
  Mona Chadha
  mona.chadha@wafergen.com
  Joyce Strand
  joyce.strand@wafergen.com
  510-651-4450

Source: WaferGen Biosystems, Inc.

CONTACT: Mona Chadha, mona.chadha@wafergen.com, or Joyce Strand,
+1-510-651-4450, joyce.strand@wafergen.com, both of WaferGen
 

Web Site: http://www.wafergen.com/

 

转载自pharmaLive


 

 

点这里复制本页地址     发送给您QQ/MSN上的好友


相关文章

  Researchers Solve Mystery of Uner Tan Sy

  Shionogi Inc. Announces FDA Approval of

  Abraxis BioScience and Specialised Thera

  Abbott's Simcor ( niacin extended-releas

  FDA Approves Drug for Chronic Drooling i

  Quintiles Announces New European Headqua

  Covance Reports Second Quarter Revenue o

  Commonwealth Biotechnologies, Inc. Provi

Plant Compound Resveratrol Shown to Supp

New pathway to Parkinson's and Alzheimer

deCODE Shows how Genetic Risk of Kidney

Bionovo to Advance Menerba to Phase 3 Cl

Geron to Proceed with First Human Clinic

Orexigen Therapeutics Announces Publicat

Basilea Pharmaceutica AG (CH) - Data on

Study Results Show That Oral Contracepti

勃林格殷格翰糖尿病药物linagliptin一项Ⅲ期

厄洛替尼在欧盟提交申请用于具EGFR 活化突变

相关评论

    
本文章所属分类:首页 研发动态